BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, Di Tanna GL. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020). Pharmacoeconomics 2020;38:1219-36. [PMID: 32812149 DOI: 10.1007/s40273-020-00952-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Heidarpour M, Sourani Z, Vakhshoori M, Bondariyan N, Emami SA, Fakhrolmobasheri M, Seyedhossaini S, Shafie D. Prognostic utility of shock index and modified shock index on long-term mortality in acute decompensated heart failure; Persian Registry of cardioVascular diseasE/Heart Failure (PROVE/HF) study. Acta Cardiol 2022;:1-10. [PMID: 35098893 DOI: 10.1080/00015385.2022.2030554] [Reference Citation Analysis]
2 Souza DS, Roman-campos D. A Importância dos Estudos de Evolução Temporal Usando Modelos Experimentais de Doenças Cardíacas. Arquivos Brasileiros de Cardiologia 2022;118:476-7. [DOI: 10.36660/abc.20210997] [Reference Citation Analysis]
3 Palacios A, Rojas-Roque C, González L, Bardach A, Ciapponi A, Peckaitis C, Pichon-Riviere A, Augustovski F. Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review. Pharmacoeconomics 2021;39:485-502. [PMID: 33782865 DOI: 10.1007/s40273-021-01014-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jain SS, Li SS, Xie J, Sutton MB, Fine JT, Edelberg JM, Gao W, Spertus JA, Cohen DJ. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ 2021;24:1115-23. [PMID: 34493144 DOI: 10.1080/13696998.2021.1978242] [Reference Citation Analysis]
5 Alghamdi A, Algarni E, Balkhi B, Altowaijri A, Alhossan A. Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study. Healthcare (Basel) 2021;9:988. [PMID: 34442125 DOI: 10.3390/healthcare9080988] [Reference Citation Analysis]
6 D'Souza PJJ, Devasia T, Paramasivam G, Shankar R, Noronha JA, George LS. Effectiveness of self-care educational programme on clinical outcomes and self-care behaviour among heart failure peoples-A randomized controlled trial: Study protocol. J Adv Nurs 2021. [PMID: 34286863 DOI: 10.1111/jan.14981] [Reference Citation Analysis]
7 Dixit NM, Shah S, Ziaeian B, Fonarow GC, Hsu JJ. Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review 2021;15:e07. [DOI: 10.15420/usc.2020.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Weinstein JM, Greenberg D, Sharf A, Simon-Tuval T. The impact of a community-based heart failure multidisciplinary team clinic on healthcare utilization and costs. ESC Heart Fail 2021. [PMID: 34747146 DOI: 10.1002/ehf2.13689] [Reference Citation Analysis]
9 Kleissl-muir S, Rasmussen B, Owen A, Zinn C, Driscoll A. Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis. Front Nutr 2022;9:865489. [DOI: 10.3389/fnut.2022.865489] [Reference Citation Analysis]
10 Silva-Cardoso J, Juanatey JRG, Comin-Colet J, Sousa JM, Cavalheiro A, Moreira E. The Future of Telemedicine in the Management of Heart Failure Patients. Card Fail Rev 2021;7:e11. [PMID: 34136277 DOI: 10.15420/cfr.2020.32] [Reference Citation Analysis]
11 Rammos A, Bechlioulis A, Kalogeras P, Tripoliti EE, Goletsis Y, Kalivi A, Blathra E, Salvo P, Trivella MG, Lomonaco T, Fuoco R, Bellagambi F, Watson CJ, Errachid A, Fotiadis DI, Michalis LK, Naka KK. Salivary Biomarkers for Diagnosis and Therapy Monitoring in Patients with Heart Failure. A Systematic Review. Diagnostics (Basel) 2021;11:824. [PMID: 34063278 DOI: 10.3390/diagnostics11050824] [Reference Citation Analysis]
12 McCullough PA, Mehta HS, Barker CM, Houten JV, Mollenkopf S, Gunnarsson C, Ryan M, Cork DP. Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction. J Comp Eff Res 2021. [PMID: 34225473 DOI: 10.2217/cer-2021-0118] [Reference Citation Analysis]
13 Ali B, Dargham S, Al Suwaidi J, Jneid H, Abi Khalil C. Temporal Trends in Outcomes of ST-Elevation Myocardial Infarction Patients With Heart Failure and Diabetes. Front Physiol 2022;13:803092. [DOI: 10.3389/fphys.2022.803092] [Reference Citation Analysis]
14 Naqvi N, Iismaa SE, Graham RM, Husain A. Mechanism-Based Cardiac Regeneration Strategies in Mammals. Front Cell Dev Biol 2021;9:747842. [PMID: 34708043 DOI: 10.3389/fcell.2021.747842] [Reference Citation Analysis]
15 Zhuang B, Shen T, Li D, Jiang Y, Li G, Luo Q, Jin Y, Shan Z, Che L, Wang L, Zheng L, Shen Y. A Model for the Prediction of Mortality and Hospitalization in Chinese Heart Failure Patients. Front Cardiovasc Med 2021;8:761605. [PMID: 34869676 DOI: 10.3389/fcvm.2021.761605] [Reference Citation Analysis]
16 Abdelmasih R, Abdelmaseih R, Thakker R, Faluk M, Ali A, Alsamman MM, Hasan SM. Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature. Cardiol Res 2021;12:210-8. [PMID: 34349861 DOI: 10.14740/cr1268] [Reference Citation Analysis]
17 Liao CT, Yang CT, Toh HS, Chang WT, Chang HY, Kuo FH, Lee MC, Hua YM, Tang HJ, Strong C, Ou HT. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region. Cardiovasc Diabetol 2021;20:204. [PMID: 34627231 DOI: 10.1186/s12933-021-01387-3] [Reference Citation Analysis]
18 Sanson G, Vellone E, Takao-Lopes C, Barrientos-Trigo S, Porcel-Gálvez AM, Riegel B, D'Agostino F. Filling a gap in standardized nursing terminology. Development of a new nursing diagnosis proposal on heart failure self-care. Int J Nurs Knowl 2021. [PMID: 33760361 DOI: 10.1111/2047-3095.12324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Caseley P, Houchens N, Gupta A. Quality and Safety in the Literature: January 2022. BMJ Qual Saf 2022;31:64-9. [PMID: 34815352 DOI: 10.1136/bmjqs-2021-014410] [Reference Citation Analysis]
20 Houchen E, Loefroth E, Schlienger R, Proudfoot C, Corda S, Saha S, Satwase SK, Studer R. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study. Cardiol Ther. [DOI: 10.1007/s40119-021-00252-4] [Reference Citation Analysis]
21 Mohammad A, Nandkeolyar S, Grewal D, Sakr A, Seliem A, Stoletniy L, Abramov D. Trial of Oral Diuretics Prior to Discharge Is Not Associated With Improved Outcomes in Decompensated Heart Failure. Cardiol Res 2021;12:244-50. [PMID: 34349866 DOI: 10.14740/cr1265] [Reference Citation Analysis]
22 Sangani D, Krupadev V, Crawford M, Deere B, Hendel R. A Quality Improvement Initiative for Increasing Cardiac Rehabilitation Referrals Using Plan-Do-Study-Act (PDSA) Methodology. Am J Med 2021:S0002-9343(21)00740-3. [PMID: 34813738 DOI: 10.1016/j.amjmed.2021.10.027] [Reference Citation Analysis]
23 Birkhoff SD, McCulloh Nair J, Bald K, Frankum T, Sanchez SR, Salvatore AL. Facilitators and challenges in the adoption of a virtual nurse visit in the home health setting. Home Health Care Serv Q 2021;40:105-20. [PMID: 33779522 DOI: 10.1080/01621424.2021.1906374] [Reference Citation Analysis]
24 Kruse CS, Beauvais BM, Brooks MS, Mileski M, Fulton LV. Models for Heart Failure Admissions and Admission Rates, 2016 through 2018. Healthcare (Basel) 2020;9:22. [PMID: 33375483 DOI: 10.3390/healthcare9010022] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Montalvo S, Gomez M, Lozano A, Arias S, Rodriguez L, Morales-acuna F, Gurovich AN. Differences in Blood Flow Patterns and Endothelial Shear Stress at the Carotid Artery Using Different Exercise Modalities and Intensities. Front Physiol 2022;13:857816. [DOI: 10.3389/fphys.2022.857816] [Reference Citation Analysis]
26 Leung AYL, Chen H, Jia Z, Li X, Shen J. Study protocol: Traditional Chinese Medicine (TCM) syndrome differentiation for heart failure patients and its implication for long-term therapeutic outcomes of the Qiliqiangxin capsules. Chin Med 2021;16:103. [PMID: 34656145 DOI: 10.1186/s13020-021-00515-1] [Reference Citation Analysis]
27 Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation 2021. [PMID: 34775784 DOI: 10.1161/CIRCULATIONAHA.121.057983] [Reference Citation Analysis]
28 Daiber A, Andreadou I, Oelze M, Davidson SM, Hausenloy DJ. Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure. Free Radical Biology and Medicine 2021;163:325-43. [DOI: 10.1016/j.freeradbiomed.2020.12.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
29 Thyagaturu HS, Bolton AR, Li S, Gonuguntla K, Kumar A, Bianco C, Balla S. Effect of Cocaine, Amphetamine and Cannabis Use Disorders on 30-day Readmissions of Patients with Heart Failure. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101189] [Reference Citation Analysis]
30 Kitsiou S, Gerber BS, Kansal MM, Buchholz SW, Chen J, Ruppar T, Arrington J, Owoyemi A, Leigh J, Pressler SJ. Patient-centered mobile health technology intervention to improve self-care in patients with chronic heart failure: Protocol for a feasibility randomized controlled trial. Contemp Clin Trials 2021;106:106433. [PMID: 33991686 DOI: 10.1016/j.cct.2021.106433] [Reference Citation Analysis]
31 Leigh JW, Gerber BS, Gans CP, Kansal MM, Kitsiou S. Smartphone Ownership and Interest in Mobile Health Technologies for Self-care Among Patients With Chronic Heart Failure: Cross-sectional Survey Study. JMIR Cardio 2022;6:e31982. [PMID: 35029533 DOI: 10.2196/31982] [Reference Citation Analysis]
32 Wickman BE, Enkhmaa B, Ridberg R, Romero E, Cadeiras M, Meyers F, Steinberg F. Dietary Management of Heart Failure: DASH Diet and Precision Nutrition Perspectives. Nutrients 2021;13:4424. [PMID: 34959976 DOI: 10.3390/nu13124424] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lin M, Zhan J, Luan Y, Li D, Shan Y, Xu T, Fu G, Zhang W, Wang M. Development and Validation of a Risk Score in Chinese Patients With Chronic Heart Failure. Front Cardiovasc Med 2022;9:865843. [DOI: 10.3389/fcvm.2022.865843] [Reference Citation Analysis]
34 Rozenbaum MH, Tran D, Bhambri R, Nativi-Nicolau J. Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy. Am J Cardiovasc Drugs 2022. [PMID: 35353352 DOI: 10.1007/s40256-022-00526-9] [Reference Citation Analysis]
35 Tisdale A, Cutillo CM, Nathan R, Russo P, Laraway B, Haendel M, Nowak D, Hasche C, Chan CH, Griese E, Dawkins H, Shukla O, Pearce DA, Rutter JL, Pariser AR. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis 2021;16:429. [PMID: 34674728 DOI: 10.1186/s13023-021-02061-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Patil T, Ali S, Kaur A, Akridge M, Eppes D, Paarlberg J, Parashar A, Jarmukli N. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF). J Cardiovasc Transl Res 2022. [PMID: 35501544 DOI: 10.1007/s12265-022-10262-9] [Reference Citation Analysis]
37 Clark H, Rana R, Gow J, Pearson M, van der Touw T, Smart N. Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review. Heart Fail Rev 2021. [PMID: 33765251 DOI: 10.1007/s10741-021-10097-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bak PG, Belenichev IF, Kucherenko LI, Abramov AV, Khromylоva OV. Morpho-functional indicators changes of rats’ myocardium in experimental doxorubicin-induced chronic heart failure and its pharmacological modulation with new 4-amino-1,2,4-triazole derivative. PHAR 2021;68:919-25. [DOI: 10.3897/pharmacia.68.e75298] [Reference Citation Analysis]